Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
AstraZeneca
Covington
Julphar
McKesson
Cerilliant
Federal Trade Commission
Harvard Business School
Dow
Accenture

Generated: February 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,162,915

« Back to Dashboard

Which drugs does patent 8,162,915 protect, and when does it expire?

Patent 8,162,915 protects NAROPIN and is included in one NDA.

This patent has twenty-two patent family members in nineteen countries.
Summary for Patent: 8,162,915
Title:Connector for packings containing medical liquids, and corresponding packing for medical liquids
Abstract: A connector for packings containing medical liquids, particularly infusion, transfusion or enteral bags, comprises a connecting part (1) for accommodating a spike for drawing out the liquid and comprises a closure part (3) that closes the passage (2) inside the connecting part (1). The connecting part (1) has an elastically deformable pinching off part (4) provided in the form of a tubular section with a non-circular cross-section. A base part (5), which widens on both sides is adjoined to said pinching off part (4) and can be integrated in the packing. During manufacturing, the packing is filled with liquid via the connecting part. After filling, the pinching off part is pressed together whereby preventing liquid from escaping. Afterwards, the closure part is placed onto the connecting part. The manufacturing of the packing is simplified by virtue of the fact that an additional tube for connecting the connector and packing is rendered unnecessary.
Inventor(s): Brandenburger; Torsten (Niddatal, DE), Heilmann; Klaus (St. Wendel, DE), Knierbein; Bernd (Neu-Anspach, DE)
Assignee: Fresenius Kabi Deutschland GmbH (Bad Homburg, DE)
Application Number:10/550,477
Patent Claim Types:
see list of patent claims
Device;

Drugs Protected by US Patent 8,162,915

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Fresenius Kabi Usa NAROPIN ropivacaine hydrochloride SOLUTION;INJECTION 020533-006 Sep 24, 1996 AP RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Fresenius Kabi Usa NAROPIN ropivacaine hydrochloride SOLUTION;INJECTION 020533-007 Sep 24, 1996 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,162,915

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany103 13 760Mar 27, 2003
PCT Information
PCT FiledJanuary 22, 2004PCT Application Number:PCT/EP2004/000487
PCT Publication Date:October 07, 2004PCT Publication Number: WO2004/084793

International Patents Family Members for US Patent 8,162,915

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2004224795 ➤ Sign Up
Brazil PI0408780 ➤ Sign Up
Germany 10313760 ➤ Sign Up
Canada 2518617 ➤ Sign Up
European Patent Office 1605891 ➤ Sign Up
Germany 502004008025 ➤ Sign Up
Denmark 1605891 ➤ Sign Up
China 1767799 ➤ Sign Up
China 100408013 ➤ Sign Up
Spain 2309491 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Federal Trade Commission
McKesson
US Department of Justice
Fish and Richardson
Dow
McKinsey
Accenture
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot